ALK and chronic myelogenous leukemia, BCR-ABL1 positive: Results were more profound in IM + ALK inhibitor combination arms, with significantly higher levels of apoptosis observed in the CML CD34+ (Fig. 4b–ii, S3E) when compared to normal CD34+ cells (Fig. 4b–i, S3E).